CRYSFORMA

Crysforma’s activity

Crysforma provides complete scientific support for the discovery, analysis and scale-up of polymorphs, hydrates, amorphous phases, salts and co-crystals of active pharmaceutical ingredients or intermediates.

Crysforma has developed its own crystallization screening methodology based on the combination of several crystallization procedures. We use high-throughput crystallization systems controlled by highly skilled scientists to maximize the information drawn from each experiment (read more).

Highlights 2015

  • Fundació Obra Social la Caixa has sponsored a project dedicated to predict to formation of pharmaceutical co-crystals which can help pre-select a set of co-crystal formers likely to form a co-crystal with a given API, and thus can help reduce the number of experiments to be performed in an experimental co-crystal screening.
CRYSFORMA

CSOL’s activity:

CSOL’s mission is to act as the link between the researchers’ expertise and the industry, as well as developing the researchers’ discoveries into industrial applications with a comprehensive approach. (read more)

Highlights 2015

During 2015 CSOL has been working on five valorization projects aimed at further developing inventions or know-how of ICIQ groups:

  • Anchoring chiral phosphoric acids to polymeric resins (Prof. Pericàs). Route optimization and scale up
  • New modular organocatalysts: Development of a reproducible and scalable route (Prof Pericàs, funding from Obra Social La Caixa)
  • Scale up of an additive to improve the electrical conductivity of polymeric matrixes incorporating carbon nanotubes (Prof Kleij)
  • Water electrolysis with low-cost catalysts using renewable energy source (Prof Galán-Mascarós, funding from Obra Social La Caixa)
  • CO2 hydrogenation at high pressure for methanol production (Prof. Urakawa, funding from Obra Social La Caixa)
CRYSFORMA

ERTFLOW is a new Technology development unit created during 2015, generated by the know-how produced by the research group of Prof Miquel Pericàs at ICIQ.

The unit’s goal is to develop proprietary technologies related to catalysis and flow chemistry and offering products and services to the fine chemical, pharmaceutical and biotechnological industries for the production of new products with high added value and guide them in the paradigm change from batch to flow, as well as to commercialize the in-house developed immobilized catalysts.

At the end of 2015 the unit was formed by Dr. Esther Alza as Unit Manager and Alba Camarasa as Unit Technician. The first industrial collaboration involving this unit was signed on December 2015.